TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Sensitivity of NIRS Optical Density Measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of NIRS Optical Density Measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Predictive Values of NIRS Measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participants With Treatment-Emergent Toxicities With a Frequency >=20% at 3 Months Post Chemotherapy
Endpoint domain: Adverse events/effects
Primary endpoint: Participants With Treatment-Emergent Toxicities With a Frequency >=20% at 6 Months Post Chemotherapy
Endpoint domain: Adverse events/effects
Primary endpoint: Change in glucose area under the curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Identification of eligible donors
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Collection of anti-SARS-CoV-2 immune plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in 15-items Geriatric Depression Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Quality of Life (WHOQOL-BREF)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Quality of Life (FLQA-d)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Quality of Life (Skindex)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Diarrhea prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Presence of Plaque Free Zone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum tolerated dose of ASN002
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in number of hospital visits
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Change in number of emergency room or urgent care visits
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in amount of oral steroids taken
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline in Arterial Fluorodeoxyglucose (FDG) Uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in central subfield thickness (CST)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in thickness of the inner retinal layer regions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in thickness of the outer retinal layer regions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 25 (OH)D
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants With Ketoacidosis
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Severe Urinary Tract Infections (UTIs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Volume Depletion
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Dehydration
Endpoint domain: Adverse events/effects
Primary endpoint: biomarkers of cardiovascular illness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Hepatic fat oxidation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Activity of ADAMTS13
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ADAMTS13 antigen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ADAMTS13 autoantibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of pelvic floor physiotherapy for Provoked Vulvar Vestibulodynia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum ctDNA levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: inflammatory phenotype
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in PhQ9
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in GAD-7
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Insomnia Severity Index
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Changes in microbial flora
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Microbial resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Time to alteration in flora
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Evidence of cognitive impairment measured by MoCA-test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Evidence of impaired Executive Functioning - Cognitive profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Evidence of slow reaction time - Cognitive profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Vaccination rates
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: safety and tolerability of adjuvant chemotherapy
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants with Pancreatitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: 24-hour urine sodium excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Loss of tooth height
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in neuropsychology test battery composite score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of pressure to reach unbearable pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Respiratory Resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change From Baseline in Urinary Albumin Excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Development of new cardiovascular diseases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pharmacokinetics of docetaxel
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Acute Chest Syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: change in secretion wet weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Boston Bowel Preparation Scale value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: patient reported acceptability score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of RBC units
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Time to clinical progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tolerability in terms of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Serum uric acid (sUA) response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Operating Time From Skin Incision to Wound Closure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Mean Arterial Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Norepinephrine (NE) Concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Myocardial T1 relaxation time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of overall infections
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Any Adverse Events (AEs), Serious Adverse Events (SAEs), AEs of Grades 3/4, and Death
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Dose Limiting Toxicity (DLT) of the Combination of T-DM1 and Paclitaxel
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Change From Baseline in Cardiac Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Best overall response (complete response + partial response)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Semen analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Adherence to the program's intervention
Endpoint domain: Life impact
Endpoint subdomain: Other resource use
Primary endpoint: Detection of clinically significant cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Adherence to breast screening recommendations
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Adherence to lifestyle risk reduction recommendations
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Time to first BC screening post-intervention
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Diagnoses made
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FDOPA uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax - Maximum Observed Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-inf - Area under the concentration-time curve from time zero to infinity (extrapolated)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-t - Area under the concentration-time curve from time zero to time of last quantifiable concentration (per participant)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Arterial Elastance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Geometric mean glucagon concentration during hypoglycaemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Bioequivalence based on AUC and Cmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of infants with fourfold or greater rises in HAI antibody titer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Erectile Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Subjects With Any and Grade 3 Solicited Local Symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Subjects With Any, Grade 3, Related and Grade 3 Related Solicited General Symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence rate of laboratory confirmed clinical cases of Malaria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percentage of Procedures Converted From Sedation to General Anesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Rate of Intra-operative Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of Adverse Events Through Discharge
Endpoint domain: Adverse events/effects
Primary endpoint: Total Morphine consumption
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: skin structure changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: All-cause Mortality
Endpoint domain: Mortality/survival
Primary endpoint: Nonfatal MI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Difference in Visual-analog Score (VAS) for Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerability of teplizumab treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Tolerance of Risk in Play Scale (TRiPS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Presence of Autism Spectrum Disorder
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Galveston Orientation and Amnesia Test (GOAT)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Glasgow Outcome Scale - Extended (GOSE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Satisfaction with Life Scale (SWL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Maternal desaturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Maximum observed plasma concentration (Cmax) of BMS-986224
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration [AUC(0-T)] of BMS-986224
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Terminal elimination half-life (T-HALF) of BMS-986224 derived from plasma concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pulmonary arterial hypertension confirmed by right heart catheterization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Biochemical markers of nutritional status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of Treatment-emergent Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with a Mayo score of 2 or less at EOT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: DRS-R-98 severity rating score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Assessment of Brain Perfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Assessment of Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Psychiatric Symptoms of Dementia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Behavioral Symptoms of Dementia
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Rate and Extend of Absorption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Achievement of desired iPTH levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Duration of epidural fentanyl
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: increase in endometrial thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Proportion of Patients Who Develop 2 or More Follicles With Diameter 16 mm or Larger
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Number of Participants With Marrow Complete Remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vasoreactivity of conduit arteries
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Risk of AL in patients with λ SMM or λ MGUS
Endpoint domain: Mortality/survival
Primary endpoint: Percent time of intragastric pH > 4.0
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: International Index of Erectile Function score (IIEF-5) improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in Serum Total testosterone level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Improvement in Penile Doppler parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cardiac imaging accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants Who Felt The Approach to Sexuality During Occupational Therapy is Relevant
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Participants That Identified Having Occupational Priorities
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Number of Participants With Problems in Performance in His/Her Daily Life
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of Participants Who Are Satisfied With Performance in Areas of Everyday Living
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: 5-year prognosis of patients undergoing coronary angiography
Endpoint domain: Mortality/survival
Primary endpoint: functional index of revascularized and non-revascularized coronary stenosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: prognosis of non-revascularized and functionally significant coronary artery disease
Endpoint domain: Mortality/survival
Primary endpoint: Time to detect V1 and V2 signals
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bacteriuria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Numeric Pain Rating Scale (NPRS) for pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional Recovery
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Reduction in measurable disease and PSA level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Long-term effectiveness of biventricular pacing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Safety of the COROX OTW Steroid LV Pacing Lead
Endpoint domain: Adverse events/effects
Primary endpoint: Qualitative assessment of loco-regional invasion of cervical cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Satisfaction in Swiss-German ICUs
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Visual Analog Scale Pain Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acceptance and preference of topical lidocaine mouth gel anesthesia
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Anatomopathologic findings of hepatic biopsies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Maturity of oocytes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Proportion of patients maintaining vision
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Color Match
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Marginal Integrity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Surface Texture
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Restoration Wear
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrent dental caries
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: The Fracture/detachment Status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) of emavusertib monotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recommended Phase 2 Dose (RP2D) of emavusertib monotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of emavusertib in combination with venetoclax
Endpoint domain: Adverse events/effects
Primary endpoint: Patient willingness to schedule and complete screening colonoscopy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Psychiatric diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence, severity, and relatedness of adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: adherence to medication regimen
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: patient satisfaction with treatment regimen
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Beta amyloid plaques
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Tau proteins
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Area Under the Plasma Concentration Versus Time Curve (AUC0-t) of Total Molybdenum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Measured Plasma Concentration (Cmax) of Total Molybdenum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Physical examination and vital signs assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical lab tests results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Endometriosis Health Profile (EHP-30)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Bodily Pain Scale (SF-36 BPS)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Visual Analog Scale for Pain (VAS PAIN)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum Etonogestrel Concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with cardiovascular adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Screening questionnaire score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status